(Press-News.org) CHICAGO, IL (May 29, 2013)—Researchers from Fox Chase Cancer Center will present data at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1, which shows the discovery of potential biomarkers that may be used to identify patients with head and neck cancer whose tumors are unlikely to respond to treatment by the targeted therapy cetuximab—a type of monoclonal antibody. The FDA approved the drug, in combination with radiation or as a second-line drug after chemotherapy had failed, in 2006. In 2011, the drug was approved as a first-line treatment for metastatic disease, in combination with chemotherapy.
"Targeted therapies should optimally be used in patients who are selected for sensitivity or the absence of sensitivity, and we've been handicapped by not knowing the resistance in head and neck cancers," says Barbara Burtness, MD, chief of head and neck medical oncology at Fox Chase and chair of the Eastern Cooperative Oncology Group (ECOG), a National Cancer Institute-funded team of researchers who organize and carry out clinical trials.
Before cetuximab, head and neck cancer patients' only options were conventional platinum-based chemotherapy and radiation, says Burtness. But since tumors in different people may have different biologies, not all patients respond to same treatment in the same ways. Those whose tumors do not respond to cetuximab suffer the drug's side effects without gaining benefits. Biomarkers can help providers match appropriate treatments to disease. They may also provide inroads toward re-sensitizing tumors to treatment by cetuximab.
She and researchers from the ECOG head and neck committee have been studying the biology of cetuximab-resistant and non-resistant tumors in search of telltale molecular signatures, or biomarkers, that might indicate if a disease will respond to the drug. The researchers have zeroed in on two potential biomarkers.
Cetuximab targets the epidermal growth factor receptor (EGFR) in a cancerous cell. When EGFR is activated, it sends signals through the cell using several pathways. Burtness and her team suspected that abnormalities in one of those pathways may be connected to cetuximab resistance. Their search for related molecules led them to a protein called PTEN and a gene called PIK3CA. They hypothesized that cells which either don't express PTEN or have a mutation in the PIK3CA gene are more likely to be unresponsive to cetuximab.
To test the biomarkers, they used tumor samples from a small phase III randomized trial that compared chemotherapy with cetuximab to chemotherapy alone for patients with head and neck cancer. That study showed that cetuximab improved responses in patients with metastatic/recurrent head and neck cancer who were receiving chemotherapy. A subsequent larger European study called EXTREME, showed that cetuximab conferred a significant survival benefit to these patients. Those studies did not identify which patients were most likely to respond to the drug.
Burtness first used tumor samples from Fox Chase Cancer Center to develop tools designed to show if a test sample had the mutation or lacked PTEN. Then, she and her collaborators analyzed 67 samples for PTEN and found 23 (34 percent) did not express the protein. The researchers studied the PIK3CA gene in 52 separate samples and found mutations in two samples (four percent). When the researchers grouped together samples that either did not express PTEN or had the PIK3CA mutation, they did not identify a significant difference in overall survival or progression-free survival, compared to the rest of the sample population.
However, the analyses suggest that for patients who expressed PTEN and lacked the PIK3CA mutation, cetuximab increased progression-free survival and overall survival each by more than a month, compared to patients lacking PTEN or with the mutation.
Burtness says these results are promising, but they're still early. "It's a small sample, and clearly more work needs to be done on larger sample sets," she says. "But we do think that this combination biomarker—the signature of PTEN loss and/or PIK3CA mutation—might point the way to those patients who are resistant to cetuximab."
A critical biomarker may also help researchers better understand the biology of tumors that don't respond to treatment with the drug. That knowledge could point to the use of other treatments, either new or existing, to re-sensitize a tumor to cetuximab.
"If you find a molecule that can be targeted that seems to produce resistance, it would make sense to look at cetuximab in combination with something that turns off the abnormality in the chemical pathway," says Burtness.
###
Other members of the research team included tumor biologist Donghua Yang and biostatistician Fang Zhu, also from Fox Chase Cancer Center; members from the Eastern Cooperative Oncology Group head and neck committee; biostatistician Ju-Whei Lee from Dana-Farber Cancer Institute in Boston; pathologist Joaquin Garcia at the Mayo Clinic in Rochester, Minnesota; medical oncologist Arlene Forastiere at Johns Hopkins Hospital in Baltimore, Maryland; and medical oncologist Christine H. Chung at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore.
Fox Chase Cancer Center, part of Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase also was among the first institutions to receive the National Cancer Institute's prestigious comprehensive cancer center designation in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are routinely recognized in national rankings, and the Center's nursing program has achieved Magnet status for excellence three consecutive times. Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research and oversees programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX-CHASE (1-888-369-2427) or visit http://www.foxchase.org. END
Researchers narrow the search for biomarkers of drug resistance in head and neck cancer patients
2013-05-31
ELSE PRESS RELEASES FROM THIS DATE:
Researchers investigate a less toxic radiation treatment for HPV-Positive oropharynx cancer
2013-05-31
CHICAGO, IL (May 29, 2013)—Researchers from Fox Chase Cancer Center and other institutions have completed a phase II clinical trial that may help identify those patients with HPV-positive oropharyngeal cancer who do not require the full radiation dose given in a standard regimen of Intensity-Modulated Radiation Therapy (IMRT). Preliminary findings will be presented by Shanthi Marur, first author on the study and an oncologist at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, at the 49th Annual Meeting of the American Society of Clinical Oncology on Sunday, ...
New therapy is tolerable in lung cancer
2013-05-31
CHICAGO, IL (May 28, 2013)—A promising new therapy for the most common form of lung cancer appears to produce largely manageable side effects, and an ongoing clinical trial is determining whether the compound treats tumors more effectively than what's on the market, according research that scientists at Fox Chase Cancer Center will present at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1.
"We're very excited about this drug," says Hossein Borghaei, DO, chief of thoracic medical oncology at Fox Chase. "I think if we learn how ...
Many solid tumors carry genetic changes targeted by existing compounds
2013-05-31
CHICAGO, IL (May 28, 2013)—Nearly two-thirds of solid tumors carry at least one mutation that may be targeted, or medicated, by an existing compound, according to new findings from researchers Fox Chase Cancer Center that will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology on June 3. The results suggest that it may one day become commonplace for doctors to sequence tumors before deciding on a treatment regimen.
"Extended sequencing of a patient's tumor is not something that's routinely done now," says study author Patrick Boland, ...
Bright light therapy may improve sleep and promote recovery in patients with mild TBI
2013-05-31
DARIEN, IL – A new study suggests that bright light therapy may improve sleep, cognition, emotion and brain function following mild traumatic brain injury (TBI).
Results show that six weeks of morning bright light therapy resulted in a marked decrease in subjective daytime sleepiness. This improvement was further associated with improvements in the propensity to fall asleep and nighttime sleep quality. Bright light therapy also affected depressive symptoms.
"Our preliminary data suggests that morning bright light therapy might be helpful to reduce subjective daytime ...
No need to battle with cattle
2013-05-31
A new study by the Wildlife Conservation Society's Animal & Human Health for the Environment And Development (AHEAD) Program, World Wildlife Fund (WWF), and regional partners finds that a new approach to beef production in southern Africa could positively transform livelihoods for farmers and pastoralists, while helping to secure a future for wildlife and wildlife-based tourism opportunities.
Market access for livestock and livestock products from Africa is constrained by the presence of foot and mouth disease (FMD). Fear of the FMD virus largely precludes large-scale ...
UCLA-led team may have found key to cause of Cushing disease
2013-05-31
FINDINGS:
Cushing disease is a life-threatening disorder most commonly triggered by tumors, often benign, in the pituitary glands, resulting in excess production of adrenocorticotrophic hormone (ACTH). The condition is marked by progressive weight gain, excessive fatty tissue deposits and a rounding of facial features, known as "moon face," and can lead to diabetes, hypertension, osteoporosis, obesity and psychological disturbances.
Cushing disease, which is more common in women than men, is also associated with a three- to four-fold increase ...
Elevated carbon dioxide making arid regions greener
2013-05-31
WASHINGTON—Scientists have long suspected that a flourishing of green foliage around the globe, observed since the early 1980s in satellite data, springs at least in part from the increasing concentration of carbon dioxide in Earth's atmosphere. Now, a study of arid regions around the globe finds that a carbon dioxide "fertilization effect" has, indeed, caused a gradual greening from 1982 to 2010.
Focusing on the southwestern corner of North America, Australia's outback, the Middle East, and some parts of Africa, Randall Donohue of the Commonwealth Scientific and Industrial ...
For first time atomic changes in a molecule during a chemical reaction photographed
2013-05-31
Taking an image of an individual molecule while it undergoes a chemical reaction has been deemed one of the holy grails of chemistry. Scientists at the University of Berkeley and the University of the Basque Country (UPV-EHU) have managed, for the very first time, to take direct, single-bond-resolved images of individual molecules just before and immediately after a complex organic reaction. The images enable appreciating the processes of the rupture and creation of links between the atoms making up a molecule. The article, entitled Direct Imaging of Covalent Bond Structure ...
The scoop on bird poop
2013-05-31
Gastrointestinal bacteria are important for digestion, immune functions and general health. Wouter van Dongen and colleagues from the Konrad Lorenz Institute of Ethology of the Vetmeduni Vienna have collaborated with scientists from the Laboratoire Évolution & Diversité Biologique (EDB), Toulouse and from the US Geological Survey, Anchorage to study the cloacal bacterial assemblies of black-legged kittiwakes (Rissa tridactyla). The bacteria in the cloaca are known to be similar to assemblages deeper within the gastrointestinal tract, so the researchers examined samples ...
Live and let die
2013-05-31
This news release is available in German.
A protein called c-FLIP-R is critical to immune cell survival: If this molecule is missing, the cells kill themselves – and are thus no longer able to perform their job fighting off invaders. Now, scientists at the Helmholtz Centre for Infection Research (HZI) Braunschweig and at the Otto von Guericke University (OvGU) Magdeburg have published their findings in the renowned European Journal of Immunology.
Apoptosis, programmed cell death, is a kind of cellular suicide program. If something triggers it, the cells perish ...